Ghazi, H. (2023). Safety and Tolerability of Sodium Glucose Co-Transporters-2 Inhibitors Among Elderly Patients with Type 2 Diabetes Fasting Ramadan. The Egyptian Journal of Hospital Medicine, 90(1), 200-205. doi: 10.21608/ejhm.2023.279312
Hossam Arafa Ghazi. "Safety and Tolerability of Sodium Glucose Co-Transporters-2 Inhibitors Among Elderly Patients with Type 2 Diabetes Fasting Ramadan". The Egyptian Journal of Hospital Medicine, 90, 1, 2023, 200-205. doi: 10.21608/ejhm.2023.279312
Ghazi, H. (2023). 'Safety and Tolerability of Sodium Glucose Co-Transporters-2 Inhibitors Among Elderly Patients with Type 2 Diabetes Fasting Ramadan', The Egyptian Journal of Hospital Medicine, 90(1), pp. 200-205. doi: 10.21608/ejhm.2023.279312
Ghazi, H. Safety and Tolerability of Sodium Glucose Co-Transporters-2 Inhibitors Among Elderly Patients with Type 2 Diabetes Fasting Ramadan. The Egyptian Journal of Hospital Medicine, 2023; 90(1): 200-205. doi: 10.21608/ejhm.2023.279312
Safety and Tolerability of Sodium Glucose Co-Transporters-2 Inhibitors Among Elderly Patients with Type 2 Diabetes Fasting Ramadan
Department of Internal Medicine, Faculty of Medicine, Mansoura University, Egypt
Abstract
Background: One of the main five pillars of Islam is Ramadan fasting and it may carry some hazards on some patients especially elderly patients. Sodium Glucose Co-Transporter-2 inhibitors (SGLT2i) is a new family which introduced in the market few years ago and used to treat patients with Type 2 Diabetes (T2D). Objective: The objective of this study is to investigate the safety and tolerability of SGLT2i among elderly patients with T2D fasting Ramadan. Patients and methods: The current study was conducted on 100 patients aged 60 years and more, both males and females (Group 1: 50 patients on vildagliptin and metformin and Group 2: 50 patients on empagliflozin and metformin). Glycated haemoglobin (HbA1c) and estimated glomerular filtration rate (eGFR) were measured before and 2 months after Ramadan. Episodes suggesting hypoglycemia and/or volume depletion were estimated. Days to break fasting were also compared. Results: The mean age among group 1 was 65.34 + 2.9 years versus 66 + 3.4 years among group 2 [P value: 0.25]. Mean HbA1c before Ramadan was 7.26±0.46 among group 1 versus 7.28±0.53 among group 2 [P value: 0.84]. No statistically significant difference was found regarding episodes suggesting hypoglycemia and/or volume depletion nor days to break fasting. Conclusion: The conducted study has addressed that SGLT2i may be used safely and well tolerated mong elderly patients with T2D fasting Ramadan if patients were well prepared and educated before Ramadan.
View on SCiNiTO
Top